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Abstract
Background: Outcome prediction is important in the clinical decision-making process. Artificial neural networks (ANN)
have been used to predict the risk of post-operative events, including survival, and are increasingly being used in
complex medical decision making. We aimed to use ANN analysis to estimate predictive factors of in-hospital mortality
(IHM) in patients with type 2 diabetes (T2DM) after major lower extremity amputation (LEA) in Spain.
Methods: We design a retrospective, observational study using ANN models. We used the Spanish National Hospital
Discharge Database to select all hospital admissions of major LEA procedure in T2DM patients. Main outcome
measures: Predictors of IHM using 4 ANN models: i) with all discharge diagnosis included in the database; ii) with all
discharge diagnosis included in the database, excluding infectious diseases; iii) comorbidities included in the Charlson
Comorbidities Index; iv) comorbidities included in the Elixhauser Comorbidity Index.
Results: From 2003 to 2013, 40,857 major LEAs in patients with T2DM were identified with a 10.0% IHM. We found that
Elixhauser Comorbidity Index model performed better in terms of sensitivity, specificity and precision than Charlson
Comorbidity Index model (0.7634 vs 0.7444; 0.9602 vs 0.9121; 0.9511 vs 0.888, respectively). The area under the ROC
curve for Elixhauser comorbidity model was 91.7% (95% CI 90.3–93.0) and for Charlson comorbidity model was 88.9%
(95% CI; 87.590.2) p = 0.043. Models including all discharge diagnosis with and without infectious diseases showed
worse results. In the Elixhauser Comorbidity Index model the most sensitive parameter was age (variable sensitive ratio
[VSR] 1.451) followed by female sex (VSR 1.433), congestive heart failure (VSR 1.341), renal failure (VSR 1.274) and chronic
pulmonary disease (VSR 1.266).
Conclusions: Elixhauser Comorbidity Index is a superior comorbidity risk-adjustment model for major LEA survival
prediction in patients with T2DM than Charlson Comorbidity Index model using ANN models. Female sex, congestive
heart failure, and renal failure are strong predictors of mortality in these patients.
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Background
In the previous decade, incidence rates of diabetes-asso-
ciated amputations have significantly decreased [1–5].
However, a major lower extremity amputation (LEA) is as-
sociated with a reduction of long-term survival and quality
of life [6, 7].
In Spain, more than 5,000 major LEAs are performed
yearly, 57% in patients with type 2 diabetes (T2DM) [8].
Despite improvements in long-term outcome, in-
hospital mortality (IHM) following major LEA in pa-
tients with T2DM has remained stable from 2001 to
2012 with figures of 9.7% and 9.5% respectively [8, 9].
Outcome prediction is important in the clinical
decision-making process. Older age, renal failure and
congestive heart failure have been identified as inde-
pendent factors for operative mortality following major
LEA in Veterans Administration patients [10]. Wise et al.
(2016) reported that preoperative septic shock and
thrombocytopenia are independent risk factors for 30-day
mortality after major LEA [11]. Other authors have de-
scribed that age and vascular disease in patients with
T2DM are important predictors that contribute to in-
crease the mortality after major LEA [12]. However, to
our knowledge, there are no studies investigating the pre-
dictive factors of in-hospital operative mortality in T2DM
patients following major LEA.
Artificial neural networks (ANN) have been used to
predict the risk of post-operative events, including sur-
vival, exploring complex relationships between preopera-
tive variables survival in different surgical settings and
are increasingly being used in complex medical decision
making [13–16].
The aim of our study was to use ANNs analysis to es-
timate predictive factors of IHM in patients with T2DM
after major LEA in Spain. We assessed the performance
indices for ANN models in four scenarios: i) with all dis-
charge diagnosis included in the database; ii) with all
discharge diagnosis included in the database, excluding
infectious diseases; iii) comorbidities included in the
Charlson Comorbidities Index (CCI) and iv) comorbidi-
ties included in the Elixhauser Comorbidity Index (ECI).
Methods
We have been used the Spanish national hospital data-
base, from 2003 to 2013 to identify predictive factors of
IHM in type 2 diabetic patients after major LEA. The
database contained variables like sex, date of birth, ad-
mission date, discharge diagnoses (up to 14), procedures
performed during the hospital stay (up to 20), length of
hospital stay (LOHS) and IHM [17]. Diagnosis and
procedures are codified according to the International
Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM). Details on this database have
been published previously [18, 19].
The study included all procedures of major amputa-
tion, defined as any LEA through or proximal to the
ankle joint (ICD-9-CM codes 84.13–84.17) in discharges
with a T2DM diagnosis (ICD-9-CM codes 250.x0; 250.x2)
in any diagnosis position. We excluded all traumatic major
LEAs (ICD-9-CM codes 895–897; 905.9; 928–929; 959 in
any diagnosis field) and patients with type 1 diabetes
(T1DM) (ICD-9-CM codes 250.x1; 250.x3).
The study sample included 40,857 patients who under-
gone major amputation procedure between January 1,
2003 and December 31, 2013.
Development of the ANN models
To provide a good quality predictive model, the data-
base has been randomly splitted in three independent
subsets: 60% of the entire database for training the
neural network (n = 24,513 cases), 20% for selecting
those models with better generalization capabilities
(n = 8,172 cases) and 20% for testing the model (n = 8,172
cases). The independent variables were age, sex, comor-
bidity and LOHS, and the dependent variable was out-
come (IHM).
The ANN used in this study was a standard feed-
forward, back-propagation neural network in which each
input layer received information from the data, then it
passed through the hidden layers and, finally, it arrived
to the output layer. We used the quasi-Newton method
in order to carry out the learning process (training
algorithm) [20] and we applied model selection to find
the optimal number of neurons in the hidden layer [21].
We elaborated four models as follow: model 1) includ-
ing all discharge diagnosis in the database; model 2) all
discharge diagnosis included in the database, except in-
fectious diseases (ICD-9-CM codes 001 to 139); model
3) comorbidities included in the CCI [22] and finally;
model 4) comorbidities included in the ECI [22].
Statistical analyses
The unit of analysis was the individual patient with
T2DM undergoing major LEA. A descriptive analysis
was performed for all variables. Categories variables are
shown as total numbers or proportions. Significant pre-
dictors were identified by bivariate analysis using chi
square test, Student's t-test or Mann–Whitney U test
when appropriate (p < 0.05, 2-tailed).
The predictive capabilities of the four models was
analyzed using the area under the ROC curve (AUC)
and the performance indices for ANN models de-
scribed in Table 3 [23]. In this context, discrimination
model is which to ability to distinguish patients who
died from those who survived. Finally, once the
model is trained, it can be studied the importance of
the input variables by performing a sensitivity ana-
lysis. The sensitivity of an input variable is calculated
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dividing the sum squared error of the neural network
responses without using the input variable by the sum
squared error of the neural network responses using all
the inputs. In this way, if the error without the input vari-
able is lower than the error using all the inputs, the value
of the sensitivity will be lower than 1 and if it is greater,
the sensitivity will be greater than 1, as described previ-
ously by Shi et al. [24].
To estimate the 95% confidence interval and to com-
pare AUC we used EPIDAT 4.2 software applying the
methods described by DeLong et al. [25, 26].
The design of the four ANNs was performed using the
predictive analytics solution Neural Designer, developed
by the authors of this work. Statistical analyses were per-
formed using the Stata MP version 10.1 statistical pack-
age (StataCorp LP, College Station, TX).
Sensitivity analysis
In order to assess the possible misclassification of
T1DM patients as T2DM or vice versa in the database
the predictive capabilities of the CCI and the ECI were
analyzed estimating the AUC including all patients with
any diabetes ICD-9-CM codes (250.xx), beside Type 1 o
Type 2.
Results
Between January 1, 2003 and December 31, 2013, a total
of 40,857 non-traumatic major LEAs (26,222 in men and
14,635 in women) corresponding to T2DM were identi-
fied in Spain. Almost 82% of the patients have ≥65 years
of age (mean age 73.77 years, SD 10.26 years).
We found that 10.0% (n = 4,078) of the patients who
died during the admission in hospital. The mean age of
patients who died during their stay was significantly
higher (76.58 years) than those survived (73.47 years).
The mean (SD) LOHS was similar, 23.10 (22.17) days
in patients who died during their hospitalization and
23.78 (22.09) days in those who survive after the proced-
ure (P > 0.05).
Table 1 shows the demographic characteristics and
prevalence of comorbidities included in the CCI accord-
ing to IHM after a major LEA in patients with T2DM.
We found that 68.83% of the patients had peripheral
vascular disease, 17.49% have renal disease and 11.52%
have chronic pulmonary disease these were the three
more common chronic conditions.
In our study IHM in women with T2DM was more
common than in diabetic men (11.7% vs. 9.0%, p < 0.05).
IHM was significantly higher in older patients (13.4%
Table 1 Demographic characteristics and prevalence of comorbidities included in the Charlson Comorbidity Index according to IHM
due to major LEA in patients with T2DM in Spain, 2003-2013
Prevalence Condition IHM% No condition IHM% p-value
Men 26222 64.2 2363 9.0 <0.001
Women 14635 35.8 1715 11.7
<50 years 805 2.0 33 4.1 <0.001
50–64 years 6702 16.4 439 6.6
65–79 years 20334 49.8 1862 9.2
≥80 years 13016 31.9 1744 13.4
Myocardial infarction 2472 6.05 393 15.9 3685 9.6 <0.001
Congestive heart failure 4384 10.73 1020 23.3 3058 8.4 <0.001
Peripheral vascular disease 28120 68.83 2648 9.4 1430 11.2 <0.001
Cerebrovascular disease 3993 9.77 524 13.1 3554 9.6 <0.001
Dementia 2373 5.81 329 13.9 3749 9.7 <0.001
Chronic pulmonary disease 4706 11.52 570 12.1 3508 9.7 <0.001
Rheumatoid disease 523 1.28 51 9.8 4027 10.0 0.860
Peptic ulcer disease 375 0.92 56 14.9 4022 9.9 <0.001
Mild liver disease 1114 2.73 149 13.4 3929 9.9 <0.001
Hemiplegia or paraplegia 248 0.61 22 8.9 4056 10.0 0.559
Renal disease 7147 17.49 1054 14.7 3024 9.0 <0.001
Any malignancy 854 2.09 95 11.1 3983 10.0 0.260
Moderate or severe liver disease 202 0.49 48 23.8 4030 9.9 <0.001
Metastatic solid tumor 157 0.38 31 19.7 4047 9.9 <0.001
AIDS/HIV 27 0.07 2 7.4 4076 10.0 0.655
P value comparing IHM between those with and without the condition. Any malignancy, including lymphoma and leukemia, except malignant neoplasm of skin
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in ≥80 years vs. 4.1% in <50 years). Patients with myocar-
dial infarction, congestive heart failure, peripheral vascular
disease, cerebrovascular disease, dementia, chronic pul-
monary disease, peptic ulcer disease, mild liver disease,
renal disease, moderate or severe liver disease or meta-
static solid tumour had significantly higher IHM than
those without these conditions (Table 1). Over 20% of the
patients suffering moderate or severe liver disease (23.8%)
and congestive heart failure (23.3%) died in the hospital
after a major LEA.
As can be seen in Table 2 when we analyse comor-
bidity included in the ECI we find that peripheral
vascular disease and hypertension (47% complicated
and 1.8% uncomplicated) were the more prevalent
diseases in diabetic patients who underwent LEAs. All
patients with any ECI (except those with paralysis,
hypothyroidism, peptic ulcer disease excluding bleed-
ing, AIDS/HIV, rheumatoid arthritis/collagen vascular
diseases, obesity, blood loss anemia, alcohol abuse or
drug abuse) have significantly higher IHM than those
without these conditions (Table 2). Beside congestive
heart failure (23.3%) patients suffering fluid and elec-
trolyte disorders (29.9%), coagulopathy (24.8%) and
pulmonary circulation disorders (21.6%) showed the
highest IHM.
The ANN-based approaches provided the 3-layer net-
works and the relative weights of neurons used for pre-
dicting IHM. Table 3 shows the ANN models in terms
of binary classification tests. The data analysis showed
that ANN model 3 and ANN model 4 have the best
Table 2 Prevalence of comorbidities included in the Elixhauser Comorbidity Index according to IHM due to major LEA in patients
with T2DM in Spain, 2003-2013
Comorbidities Prevalence Condition IHM No condition IHM p-value
Congestive heart failure 4384 10.7 1020 23.3 3058 8.4 <0.001
Cardiac arrhythmias 7552 18.5 1079 14.3 2999 9.0 <0.001
Valvular disease 1716 4.2 244 14.2 3834 9.8 <0.001
Pulmonary circulation disorders 500 1.2 108 21.6 3970 9.8 <0.001
Peripheral vascular disorders 28120 68.8 2648 9.4 1430 11.2 <0.001
Hypertension, uncomplicated 19204 47.0 1616 8.4 2462 11.4 <0.001
Hypertension, Complicated 5220 12.8 720 13.8 3358 9.4 <0.001
Paralysis 248 0.6 22 8.9 4056 10.0 0.559
Other neurological disorders 1268 3.1 174 13.7 3904 9.9 <0.001
Chronic pulmonary disease 4706 11.5 570 12.1 3508 9.7 <0.001
Hypothyroidism 867 2.1 84 9.7 3994 10.0 0.771
Renal failure 7125 17.4 1052 14.8 3026 9.0 <0.001
Liver disease 1316 3.2 197 15.0 3881 9.8 <0.001
Peptic ulcer disease excluding bleeding 223 0.5 23 10.3 4055 10.0 0.868
AIDS/HIV 27 0.1 2 7.4 4076 10.0 0.655
Lymphoma 70 0.2 2 2.9 4076 10.0 0.047
Metastatic cancer 157 0.4 31 19.7 4047 9.9 <0.001
Solid tumor without metastasis 817 2.0 107 13.1 3971 9.9 0.003
Rheumatoid arthritis/collagen vascular diseases 686 1.7 72 10.5 4006 10.0 0.650
Coagulopathy 270 0.7 67 24.8 4011 9.9 <0.001
Obesity 1898 4.6 195 10.3 3883 10.0 0.663
Weight Loss 542 1.3 106 19.6 3972 9.9 <0.001
Fluid and electrolyte disorders 1043 2.6 312 29.9 3766 9.5 <0.001
Blood loss anemia 209 0.5 30 14.4 4048 10.0 0.034
Deficiency anemia 922 2.3 112 12.1 3966 9.9 0.026
Alcohol abuse 1841 4.5 165 9.0 3913 10.0 0.136
Drug abuse 57 0.1 5 8.8 4073 10.0 0.761
Psychoses 292 0.7 25 8.6 4053 10.0 0.417
Depression 1429 3.5 112 7.8 3966 10.1 0.006
P value comparing IHM between those with and without the condition
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accuracy rate (0.8612 and 0.8307) and ECI model per-
formed better in terms of sensitivity, specificity and pre-
cision than CCI model (0.7634 vs 0.7444; 0.9602 vs
0.9121; 0.9511 vs 0.888, respectively).
Compared with CCI model, ECI model showed a sig-
nificantly better (p = 0.043) area under the ROC curve
(91.7% [95% CI 90.3–93.0] vs 88.9% [95% CI; 87.5–90.2])
as can been seen in Fig. 1. The area under the curve for
models 1 and 2 were 0.87 and 0.867, respectively, show-
ing that these models are less accurate to predict IHM
after major LEAS using ANN.
The selection data set was also used to calculate the
variable sensitive ratio (VSR). Table 4 presents the VSR
values for the outcome variable (IHM) regarding CCI and
ECI comorbidities. In the ECI network for predicting
IHM, the most sensitive parameter was age (VSR 1.451)
followed by female sex (VSR 1.433), congestive heart
failure (VSR 1.341), renal failure (VSR 1.274) and
chronic pulmonary disease (VSR 1.266). Age, female
sex, myocardial infarction, renal disease and congestive
heart failure were the predictors of IHM with the CCI net-
work. All VSR exceeded 1, which indicated that the net-
work performs better when all variables were considered.
The sensitivity analysis, including all diabetic patients
beside if codified as Type 1(n = 1531; 3.61%) or Type 2
(n = 40,857; 96.39%), showed that the AUC for the ECI
was 90.1% (95% CI 88.9–91.3) and for the CCI was
86.9% (95% CI 85.7%–88.2%) (p = 0.026).
Table 3 Comparison of performance indices for Artificial Neural Network models when using new data sets for predicting in
hospital mortality rate in patients with T2DM after major LEA in Spain
Indices Description Model 1 Model 2 Model 3 Model 4
Accuracy rate Ratio of instances correctly classified 0.807 0.794 0.830 0.861
Error rate Ratio of instances misclassified 0.192 0.205 0.169 0.138
Sensitivity Portion of actual positive which are predicted positive 0.775 0.801 0.744 0.763
Specificity Portion of actual negative predicted negative 0.838 0.786 0.912 0.960
Precision Portion of predicted positive which are actual positive 0.821 0.787 0.888 0.951
Positive likelihood Likelihood that a predicted positive is an actual positive 4.794 3.756 8.476 19.23
Negative likelihood Likelihood that a predicted negative is an actual negative 3.733 3.962 3.569 4.06
F1 score Harmonic mean of precision and sensitivity 0.797 0.794 0.810 0.847
False positive rate Portion of actual negative which are predicted positive 0.161 0.213 0.087 0.039
False discovery rate Portion of predicted positive which are actual negative 0.178 0.212 0.111 0.048
False negative rate Portion of actual positive which are predicted negative 0.224 0.198 0.255 0.236
Negative predictive value Portion of predicted negative which are actual negative 0.795 0.800 0.790 0.800
Matthews correlation Correlation between the targets and the outputs. It takes a
value between -1 and +1
0.615 0.588 0.668 0.737
Informedness Probability that the prediction method will make a correct
decision as opposed to guessing
0.613 0.588 0.656 0.723
Markedness Probability of predicting the classifier labels from the real classes. 0.659 0.574 0.801 0.911
Model 1: all discharge diagnosis included in the database. Model 2: all discharge diagnosis included in the database, except infectious diseases (ICD-9-CM codes
001 to 139). Model 3: comorbidities included in the Charlson Comorbidities Index. Model 4: comorbidities included in the Elixhauser Comorbidities Index
Fig. 1 Area under the ROC curve of the Charlson comorbidities index model and the Elixhauser comorbidities index model in predicting the
in-hospital mortality rate after major LEA in patients with T2DM in Spain
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Discussion
To our knowledge, this study is the first to use a na-
tionwide population-based discharge database to train
and test an ANN for predicting factors of IHM in
type 2 diabetic patients after major LEAs. We
assessed and compared the two most commonly used
comorbidity risk adjustment models in surgery, the
Charlson and Elixhauser measures, regarding their
ability to predict in-hospital death [22].
Like in other surgical procedures it is necessary to ap-
propriately adjust for T2DM patient risk, recognizing
that the underlying nature of some patients’ conditions
may make them more likely than others to experience
poor outcomes. Using ANNs we found that the ECI is a
superior comorbidity risk-adjustment model for major
lower extremity amputation in-hospital mortality
compared with the CCI measure. Although differences
in the area under the ROC curve between the two
comorbidity-based measures were small, it has been
noted that even slight improvements in area under
the ROC curve for such indexes can translate into
quantificable reductions in confounding bias [27].
Overall, the area under the ROC curve for inpatient
mortality for the Charlson and Elixhauser comorbidity-
based measures in our study were high and comparable to
those described in other patient population [28, 29].
Major LEA in T2DM patients is associated with sig-
nificant mortality. Our IHM of 10.0% is consistent with
previously reported data ranging from 7% to 12.4%
[7, 10, 30–33]. Investigation of underlying influences
from health services, surgical decisions and patient
motivations behind decisions to amputate might help
to explain some of the differences in post-operative
mortality rates between studies [34].
The effect of advancing age on IHM is also highlighted
in this study, as has been well established by other au-
thors [7, 10, 30]. Older age is associated with high preva-
lence of comorbid conditions, mainly cardiovascular and
renal diseases, both of which are also associated with
higher mortality rates [32, 35].
Despite having lower incidence rates of major LEAs
several studies, including ours, suggest that women
have higher mortality rates associated with diabetes-
related LEAs [36, 37]. In US have reported that
women had higher IHM associated with diabetes-
related LEAS (37.7 IHM/1000 amputations vs. 29.7/
1000 amputations [38]. Some previous research sug-
gests higher LEA-associated cardiovascular disease
mortality risk, including atherosclerotic complications,
among women with LEAs [35, 38–40].
Several studies have evaluated specific comorbid dis-
eases associated with reduced survival after major LEA
[30–35, 38, 40]. Patients who needed major amputations
suffered from a more severe cardiovascular disease than
others [36]. Previous studies in Spain, significant risk
factors for IHM were cardiac and respiratory complica-
tions and first episode of amputation [41]. Schofield et al.
concluded that diabetic amputees have a greater risk of
heart failure (OR: 2.26; 95% CI 1.12–4.57) further amputa-
tion and death than nondiabetic amputees [12] and
highlighted the need for a more aggressive approach in
the management of cardiovascular risk factors in those
who undergo amputation and have diabetes. A recent
study in the Canadian population reported that predictors
of prolonged hospital stay included cardiovascular risk
factors, such as diabetes, hypertension, ischemic heart dis-
ease, congestive heart failure or hyperlipidemia [42].
Different studies have identified renal disease as a risk
factor for a significantly lower long-term survival after a
major LEA [6, 36, 43–46]. Recently, Assi et al. reported
that patients with chronic kidney disease have higher
risk (OR 2.27; 95% CI 1.02–5.06) of postoperative long-
term mortality and concluded that how CKD contributes
to worse survival is unclear [31].
Other factor that has been found associated to mortal-
ity after amputations among people with diabetes was
chronic pulmonary disease. Shah et al. demonstrated
that several independent factors were detrimental to sur-
vival (at 24 months) including chronic obstructive pul-
monary disease (hazard ratio [HR] 1.82, P = 0.002),
Table 4 Global sensitivity analysis of the Charlson comorbidities index model and the Elixhauser comorbidities index model in
predicting the in-hospital mortality rate after major LEA in patients with T2DM in Spain
Charlson model Elixhauser model
Variable ranking Variable VSR Variable VSR
1st Age 1.577 Age 1.451
2nd Female 1.559 Female 1.433
3rd Myocardial infarction 1.477 Congestive heart failure 1.341
4th Renal disease 1.456 Renal failure 1.274
5th Congestive heart failure 1.447 Chronic pulmonary disease 1.266
6th Moderate or severe liver disease 1.412 Liver disease 1.262
7th Metastatic solid tumor 1.362 Metastatic cancer 1.246
VSR Variable sensitivity ratio
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dialysis dependence (HR 2.50, P < 0.001), high cardiac
risk (HR 2.20, P < 0.001), and guillotine amputation
(HR 2.49, P = 0.004) [33].
The strength of our study lies in its large sample size
and in the use of ANN models. Different studies indi-
cated that ANN models can simultaneously process
numerous variables and can consider outliers and non-
linear interactions among variables. Therefore, whereas
conventional statistics reveal parameters that are signifi-
cant only for the overall population, the ANN model in-
cludes parameters that are significant at the individual
level even if they are not significant in the overall popu-
lation [13–16].
One of the major limitations of our study is that our
data source was the CMBD, which contains administrative
discharge data for hospitalizations in Spain and uses infor-
mation the physician included in the discharge report. In
our data we have no information about detailed clinical
variables like glycemic control or lifestyle variables like
smoking habits. Nevertheless, the CMBD, are periodically
audited and the validity of our dataset has been assessed
and shown to be useful for health research [47].
Another possible limitation is that a misclassification
bias may occur and some patients suffering T2DM may
have been recorded as T1DM or vice versa. In our inves-
tigation we excluded T1DM patients because in our
database only 1531 patients had the codes for T1DM re-
corded, representing the 3.61% of all mayor amputations
analyzed. Furthermore, patients with T1DM were signifi-
cantly younger (mean age 66.56 years vs. 73.77 years;
p < 0.001) and had less co-morbidities (mean CCI 1.25 vs.
1.39 and mean ECI 1.90 vs. 2.27; both p < 0.001) than
those with T2DM. However, the results of the sensitivity
analysis showed very similar results suggesting that the
misclassification bias would not affect the main conclu-
sions of our study.
Conclusions
In conclusion, using ANN models we found that ECI
method is a superior comorbidity risk-adjustment model
for major LEA survival prediction in patients with
T2DM than Charlson comorbidity. The global sensitivity
analysis with the ECI model showed that the more pre-
dictors of IHM after major LEA procedure were older
age followed by female sex, congestive heart failure,
renal failure, chronic pulmonary disease, liver disease
and metastatic cancer. The predictors analyzed in this
study could be addressed in preoperative and postopera-
tive health care of patients with T2DM candidates for
major LEA.
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